The Knee Osteoarthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Knee Osteoarthritis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Knee Osteoarthritis Market.

Some of the key takeaways from the Knee Osteoarthritis Pipeline Report: 

• Companies across the globe are diligently working toward developing novel Knee Osteoarthritis treatment therapies with a considerable amount of success over the years. 

• Knee Osteoarthritis companies working in the treatment market are Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfields Pharma, Biosplice Therapeutics, and others, are developing therapies for the Knee Osteoarthritis treatment 

• Emerging Knee Osteoarthritis therapies in the different phases of clinical trials are- M6495, PPV 06, LG00034053, StroMel, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, and others are expected to have a significant impact on the Knee Osteoarthritis market in the coming years.   

• In September 2024, Cytonics has announced the completion of subject enrollment for its Phase I clinical trial of CYT-108, a potential disease-modifying therapy for knee osteoarthritis (OA). CYT-108 is a recombinant variant of the alpha-2-macroglobulin blood serum protease inhibitor. The company initiated this Phase I trial in July, which is a first-in-human, multicenter, six-month, double-blind, randomized controlled trial (RCT) aimed at evaluating the safety and efficacy of CYT-108 in patients with unilateral, mild-to-moderate primary OA of the knee.

• In June 2024, Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage company focused on macrophage reprogramming immunotherapy, announced a positive interim data update from a Phase I/II investigator-initiated clinical trial of Allocetra™ in patients with end-stage knee osteoarthritis who were candidates for knee replacement surgery.

Knee Osteoarthritis Overview

Knee osteoarthritis is a degenerative joint disease that occurs when the protective cartilage in the knee joint wears down over time. This leads to pain, stiffness, swelling, and reduced mobility. The condition is most common in older adults but can also affect younger individuals due to injury or genetic factors. Risk factors include age, obesity, previous knee injuries, and family history. Symptoms often worsen with activity and improve with rest. Treatment options include physical therapy, pain management with medications, lifestyle changes like weight loss, and in severe cases, surgical interventions such as knee replacement.

Get a Free Sample PDF Report to know more about Knee Osteoarthritis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/knee-osteoarthritis-pipeline-insight

Emerging Knee Osteoarthritis Drugs Under Different Phases of Clinical Development Include:

• M6495: Merck KGaA

• PPV 06: Peptinov

• LG00034053: LG Chem

• StroMel: Akan Bioscience

• TTAX03: BioTissue,Inc.

• EP-104IAR: Eupraxia Pharmaceuticals Inc.

• OLP 1002: OliPass Corporation

• JTA-004: Bone Therapeutics

• X 0002: Techfields Pharma

• Lorecivivint: Biosplice Therapeutics

Knee Osteoarthritis Route of Administration

Knee Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Knee Osteoarthritis Molecule Type

Knee Osteoarthritis Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy 

Knee Osteoarthritis Pipeline Therapeutics Assessment

• Knee Osteoarthritis Assessment by Product Type

• Knee Osteoarthritis By Stage and Product Type

• Knee Osteoarthritis Assessment by Route of Administration

• Knee Osteoarthritis By Stage and Route of Administration

• Knee Osteoarthritis Assessment by Molecule Type

• Knee Osteoarthritis by Stage and Molecule Type

DelveInsight’s Knee Osteoarthritis Report covers around 40+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Knee Osteoarthritis product details are provided in the report. Download the Knee Osteoarthritis pipeline report to learn more about the emerging Knee Osteoarthritis therapies

Some of the key companies in the Knee Osteoarthritis Therapeutics Market include:

Key companies developing therapies for Knee Osteoarthritis are – Eli Lilly and Company, Nature Cell Co. Ltd., Novo Nordisk A/S, Flexion Therapeutics, Inc., Grünenthal GmbH, Tissue Tech Inc., Kolon TissueGene, Inc., Bioventus LLC, Akan Biosciences, LLC, Genascence Corporation, Immunis, Inc., Novartis, Biosplice Therapeutics, Sorrento Therapeutics, Inc., Novartis, Celltex Therapeutics Corporation, MiMedx Group, Inc., Rho, Inc., Techfields Pharma Co. Ltd, Saol Therapeutics Inc, Centrexion Therapeutics, Taiwan Liposome Company, MiMedx, Ampio Pharmaceuticals, ReNu, Medipost, and others.

Knee Osteoarthritis Pipeline Analysis:

The Knee Osteoarthritis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Knee Osteoarthritis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Knee Osteoarthritis Treatment.

• Knee Osteoarthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Knee Osteoarthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Knee Osteoarthritis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Knee Osteoarthritis drugs and therapies

Knee Osteoarthritis Pipeline Market Drivers

• Increase in prevalence of Osteoarthritis, robust Knee Osteoarthritis Pipeline are some of the important factors that are fueling the Knee Osteoarthritis Market.

Knee Osteoarthritis Pipeline Market Barriers

• However, risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment, high cost associated with the treatment and other factors are creating obstacles in the Knee Osteoarthritis Market growth.

Scope of Knee Osteoarthritis Pipeline Drug Insight    

• Coverage: Global

• Key Knee Osteoarthritis Companies: Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfields Pharma, Biosplice Therapeutics, and others

• Key Knee Osteoarthritis Therapies: M6495, PPV 06, LG00034053, StroMel, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, and others

• Knee Osteoarthritis Therapeutic Assessment: Knee Osteoarthritis current marketed and Knee Osteoarthritis emerging therapies

• Knee Osteoarthritis Market Dynamics: Knee Osteoarthritis market drivers and Knee Osteoarthritis market barriers 

Request for Sample PDF Report for Knee Osteoarthritis Pipeline Assessment and clinical trials

Table of Contents

1. Knee Osteoarthritis Report Introduction

2. Knee Osteoarthritis Executive Summary

3. Knee Osteoarthritis Overview

4. Knee Osteoarthritis- Analytical Perspective In-depth Commercial Assessment

5. Knee Osteoarthritis Pipeline Therapeutics

6. Knee Osteoarthritis Late Stage Products (Phase II/III)

7. Knee Osteoarthritis Mid Stage Products (Phase II)

8. Knee Osteoarthritis Early Stage Products (Phase I)

9. Knee Osteoarthritis Preclinical Stage Products

10. Knee Osteoarthritis Therapeutics Assessment

11. Knee Osteoarthritis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Knee Osteoarthritis Key Companies

14. Knee Osteoarthritis Key Products

15. Knee Osteoarthritis Unmet Needs

16 . Knee Osteoarthritis Market Drivers and Barriers

17. Knee Osteoarthritis Future Perspectives and Conclusion

18. Knee Osteoarthritis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/